Investment
Features
FeesSafety
Academy
More
Pluang+

ACRES Commercial Realty approves $5M more for share buyback program

Company Fundamentals
29 Sep 2026
PRNewsWire
View Source
Bullish
ACRES Commercial Realty approves $5M more for share buyback program

ACRES Commercial Realty Corp. announced its board approved an additional $5 million for its existing share repurchase program. The company plans to buy back shares through various methods depending on market conditions but has not set a specific timeline. This move reflects ACRES' strategy to manage its capital and potentially increase shareholder value. Investors should watch for future buyback activity as market conditions evolve.

ACRES Commercial Realty Corp.'s share repurchase program update provides context for readers. For those tracking Real Estate sector stocks on Pluang, as of Sep 30, 2026 02:02 WIB, 6 of 26 priced US Real Estate stocks rose while 20 fell. Notable prices include NLY at USD 20.26 with 0% Sell / 100% Buy order activity, ONL at USD 2.50 with 21% Sell / 79% Buy, and AMT at USD 167.38 with 0% Sell / 100% Buy activity.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
43 minutes ago
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...

Company Fundamentals
Bullish
2 hours ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
3 hours ago
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
Bearish
3 hours ago
Simmons First National to report Q3 2026 earnings on Oct 15 with a conference call on Oct 16

Simmons First National to report Q3 2026 earnings on Oct 15 with a conference call on Oct 16

Simmons First National Corporation announced it will release its third quarter 2026 earnings after market close on October 15, 2026. Management will hold a live conference call on October 16 to discuss the results, accessible via phone and online. Si...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App